Results 141 to 150 of about 13,000,271 (286)
Spontaneous urinary bladder rupture in a dog with lymphoplasmacytic cystitis
Journal of Small Animal Practice, EarlyView.A 10‐year‐old male mixed‐breed dog presented with vomiting and anuria. The dog was living indoors, and no trauma was reported by the owner. Ultrasonography and a retrograde urethrogram revealed the presence of a urinary bladder leakage. A celiotomy was performed to repair a urinary bladder tear, along with a biopsy of the urinary bladder wall ...
C. Donà +6 more
wiley +1 more source
Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review
Clinical and Applied Thrombosis/HemostasisBackground Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of coagulation factors VIII and IX, respectively. These conditions lead to spontaneous bleeding, joint damage, inhibitor development, and the burden of ...
Erum Siddiqui MBBS +5 more
doaj +1 more source
Molecular diagnosis of hemophilia A and B. Report of five families from Costa Rica
Revista de Biología Tropical, 2004 Hemophilia Aand B are X-chromosome linked bleeding disorders caused by deficiency of the respective coagulation factor VIII and IX. Affected individuals develop a variable phenotype of hemorrhage caused by a broad range of mutations within the Factor ...
Lizbeth Salazar-Sánchez +8 more
doaj
Marstacimab for the Treatment of Hemophilia A or B
Biologics: Targets and TherapyHemophilia A and B, caused by deficiencies of coagulation factors VIII or IX, result in impaired thrombin generation with consequent spontaneous or trauma-related bleeding, particularly hemarthroses. Although prophylactic factor replacement therapy remains the global standard of care for hemophilia, it has significant limitations, including intravenous
openaire +2 more sources
Vox Sanguinis, EarlyView.Abstract Plasma‐derived medicinal products (PDMPs), particularly immunoglobulins (Igs), are essential treatments for numerous diseases, often serving as the primary therapeutic option and playing a critical role in patient care. The human origin of these products, however, can lead to supply constraints due to a lack of plasma collection, market ...
Miriam Belmonte +4 more
wiley +1 more source
Discussion:Future Considerations in the Management of Hemophilia B [PDF]
, 1995 openalex +1 more source
Rapid Communications in Mass Spectrometry, Volume 39, Issue 18, 30 September 2025.ABSTRACT Desmopressin (DDAVP), which indirectly increases Coagulation Factor VIII concentrations in the blood, is a common treatment for bleeding disorders such as von Willebrand disease or hemophilia A. However, DDAVP exhibits significant variability in response due to interindividual differences in pharmacokinetics.
Sophie Hodin +7 more
wiley +1 more source
Nine independentF9 mutations in the Mexican hemophilia B population: Nonrandom recurrences of point mutation events in the human germline [PDF]
, 2000 Ana Rebeca Jaloma‐Cruz +9 more
openalex +1 more source